T-VEC
Aliases
946414-94-4, ABP 206, BCD-263, BMS-936558, CMAB819 (13 other aliases)
347 clinical trials
4 abstracts
728 indications
Indication
Small Cell Lung CancerIndication
Hodgkin lymphomaIndication
NeoplasmIndication
Peritoneal NeoplasmIndication
Malignant Retroperitoneal NeoplasmIndication
Cervical CancerIndication
Endometrial CarcinomaIndication
Fallopian Tube CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Peritoneal CarcinomatosisIndication
Platinum-Refractory Ovarian CarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Recurrent Cervical CarcinomaIndication
Endometrial CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Fallopian Tube Cancer, Stage IV, AJCC v8Indication
Stage IV Ovarian CancerIndication
Primary Peritoneal Cancer (Stage IV)Indication
Stage IV Fallopian Tube Cancer AJCC v8Indication
Stage IV Ovarian Cancer AJCC v8Indication
Stage IVB Cervical Cancer AJCC v8Indication
Fallopian Tube CancerIndication
Ovarian Cancer Stage IVB AJCC v8Indication
Recurrent Head and Neck CarcinomaIndication
Locally Advanced Head and Neck CarcinomaIndication
Stage IVB Uterine Corpus Cancer AJCC v8Indication
Hodgkin LymphomaIndication
Hodgkin's LymphomaIndication
Multiple MyelomaIndication
Colorectal AdenocarcinomaIndication
Mucinous AdenocarcinomaIndication
Signet Ring Cell AdenocarcinomaIndication
Melanoma stage IIIIndication
melanomaIndication
Hodgkin lymphoma, Ann Arbor stage IBIndication
Hodgkin Lymphoma Stage IIIndication
Hodgkin Lymphoma, Ann Arbor Stage IIBIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Hodgkin Lymphoma, Ann Arbor Stage IVAIndication
Stage IVB Hodgkin LymphomaIndication
Acute bilineal leukemiaIndication
Acute Biphenotypic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Myelodysplastic SyndromeIndication
Recurrent Acute Myeloid LeukemiaIndication
Acute Myeloid LeukemiaIndication
Therapy-Related Acute Myeloid LeukemiaIndication
Metastatic MelanomaIndication
Skin CancerIndication
Triple-Negative Breast CancerIndication
CarcinomaIndication
Renal Medullary CarcinomaIndication
Prostate CancerIndication
ALK-Positive Large B-Cell LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
NOSIndication
Kaposi sarcoma-associated herpesvirusIndication
High-Grade B-Cell LymphomaIndication
Intravascular Large B-Cell LymphomaIndication
Plasmablastic LymphomaIndication
Primary Effusion LymphomaIndication
Recurrent B-Cell Non-Hodgkin LymphomaIndication
Burkitt LymphomaIndication
MelanomaIndication
Mucosal melanomaIndication
Metastatic Malignant Skin NeoplasmIndication
Endometrial NeoplasmsIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Gray-Zone LymphomaIndication
Recurrent High Grade B-Cell LymphomaIndication
High Grade B-Cell LymphomaIndication
B-cell lymphoma 2Indication
BCL6 RearrangementsIndication
Lymphomatoid GranulomatosisIndication
Leg TypeIndication
B-Cell Non-Hodgkin LymphomaIndication
Burkitt lymphomaIndication
Refractory Gray-Zone LymphomaIndication
Refractory High Grade B-Cell LymphomaIndication
Cutaneous Diffuse Large B-Cell LymphomaIndication
LymphomaIndication
Lung CancerIndication
Pancreatic CancerIndication
Esophageal Squamous Cell CarcinomaIndication
Hormone Receptor-positive Breast CancerIndication
Tissue Factor-Expressing Solid TumorsIndication
Hepatocellular CarcinomaIndication
Malignant NeoplasmIndication
Anal CancerIndication
HIV InfectionIndication
Kaposi SarcomaIndication
Metastatic Malignant Solid NeoplasmIndication
Diffuse Intrinsic Pontine GliomaIndication
GliomaIndication
Diffuse Midline GliomaIndication
H3 K27M-MutantIndication
MedulloblastomaIndication
EpendymomaIndication
Pineal Region TumorsIndication
Choroid Plexus TumorsIndication
Atypical/Malignant MeningiomaIndication
Brain MetastasesIndication
Renal Cell CarcinomaIndication
Pancreatic Ductal AdenocarcinomaIndication
MetastaticIndication
Human PapillomavirusIndication
Squamous Cell CarcinomaIndication
HPV-Related Squamous Cell CarcinomaIndication
HNSCCIndication
cancerIndication
Renal CellIndication
Head and Neck NeoplasmIndication
Skin NeoplasmsIndication
Microsatellite InstabilityIndication
Penile NeoplasmsIndication
EGFR gene mutationIndication
Recurrent Non-Small Cell Lung CarcinomaIndication
Stage IIIA Non-Small Cell Lung CancerIndication
Stage IIIB Non-Small Cell Lung CancerIndication
Stage IV Non-Small Cell Lung CancerIndication
AdenocarcinomaIndication
Stage IVIndication
Lymph Node CancerIndication
Stage IV Cutaneous MelanomaIndication
Colorectal CancerIndication
Colorectal cancerIndication
Ovarian Cancer Stage 3Indication
Recurrent CNS LymphomaIndication
Central Nervous System LymphomaIndication
Lung NeoplasmIndication
Colon CancerIndication
Rectal CancerIndication
Rectal AdenocarcinomaIndication
Borderline ResectableIndication
Metastatic Urothelial CancerIndication
Nasopharyngeal CarcinomaIndication
CancerIndication
Stage III Renal Cell Cancer AJCC v8Indication
Stage IV Renal Cell Cancer AJCC v8Indication
Thyroid CarcinomaIndication
Head and Neck CarcinomaIndication
Lung Non-Small Cell CarcinomaIndication
Thyroid Medullary CarcinomaIndication
Triple-Negative Breast CarcinomaIndication
Skin Squamous Cell CarcinomaIndication
GlioblastomaIndication
Malignant GliomaIndication
Recurrent Malignant GliomaIndication
Recurrent Grade III GliomaIndication
Grade III GliomaIndication
Colon Carcinoma with Liver MetastasisIndication
Pancreatic adenocarcinomaIndication
Pancreatic Cancer, Stage IIIndication
Stage IIB Pancreatic CancerIndication
Stage III Pancreatic CancerIndication
Colorectal Cancer, Stage IVBIndication
Bladder CancerIndication
Breast CancerIndication
Breast Cancer, Stage IVIndication
Castration-Resistant Prostate CarcinomaIndication
Thyroid CancerIndication
Metastatic Head and Neck CarcinomaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Small Cell Lung CarcinomaIndication
Metastatic Urothelial CarcinomaIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Recurrent Lung Small Cell CarcinomaIndication
Recurrent Malignant Solid NeoplasmIndication
Medullary CarcinomaIndication
Recurrent Urothelial CarcinomaIndication
Stage III Lung Cancer AJCC v8Indication
Stage III Ovarian Cancer AJCC v8Indication
Prostate Cancer, Stage III AJCC v8Indication
Thyroid Gland Medullary CarcinomaIndication
Stage IV Lung CancerIndication
BRAF V600 MutationIndication
Head and Neck Squamous Cell CarcinomaIndication
NeuroblastomaIndication
Non-Hodgkin LymphomaIndication
OsteosarcomaIndication
RhabdomyosarcomaIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
Stage III Cutaneous Melanoma AJCC v7Indication
Stage IIIA Cutaneous Melanoma AJCC v7Indication
Cutaneous MelanomaIndication
Fibrolamellar Hepatocellular CarcinomaIndication
Head and Neck CancerIndication
Ewing SarcomaIndication
Pediatric Solid TumorIndication
hepatoblastomaIndication
Wilms tumorIndication
Genitourinary CancerIndication
Adrenocortical CancerIndication
Upper Tract Urothelial CarcinomaIndication
Penile CancerIndication
Refractory Germ-cellIndication
Neuroendocrine CarcinomaIndication
Advanced Soft Tissue SarcomaIndication
Soft Tissue SarcomaIndication
Liver MetastasesIndication
Stomach CancerIndication
MSI-HIndication
Metastatic CancerIndication
Advanced CancerIndication
Bone SarcomaIndication
Dedifferentiated LiposarcomaIndication
Gastrointestinal Stromal TumorIndication
LiposarcomaIndication
Metastatic Unresectable SarcomaIndication
Pleomorphic LiposarcomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Bone Sarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Stage IVB Bone Sarcoma AJCC v7Indication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Bladder Urothelial CarcinomaIndication
Renal Pelvis Urothelial CarcinomaIndication
Ureter Urothelial CarcinomaIndication
Urethral Urothelial CarcinomaIndication
Urothelial CarcinomaIndication
Advanced Nonsmall Cell Lung CancerIndication
Metastatic Bladder Urothelial CarcinomaIndication
Epigenetic TherapyIndication
pan-tumorIndication
PD-L1 Gene AmplificationIndication
FGFR2 AmplificationIndication
lymphomaIndication
Metastatic Renal Cell CarcinomaIndication
Bladder CarcinomaIndication
Stage III LymphomaIndication
Stage III Non-Small Cell Lung CancerIndication
Renal Cell CancerIndication
Stage IIIA Skin MelanomaIndication
Stage IIIB skin melanomaIndication
Stage IIIC Skin MelanomaIndication
Stage IV Renal Cell CancerIndication
Skin MelanomaIndication
Stage IV Bladder CancerIndication
Stage I Hodgkin LymphomaIndication
Esophageal adenocarcinomaIndication
Esophageal cancerIndication
HER2 Protein OverexpressionIndication
Gastroesophageal Junction CancerIndication
Grade 2 meningiomaIndication
Grade 3 MeningiomaIndication
MeningiomaIndication
Melanoma of Unknown PrimaryIndication
Metastatic Mucosal MelanomaIndication
Ocular MelanomaIndication
LeukemiaIndication
myeloidIndication
AcuteIndication
Myelodysplastic SyndromesIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Mixed Phenotype Acute LeukemiaIndication
Stage IIIA Hepatocellular CarcinomaIndication
Fibrolamellar CarcinomaIndication
Hodgkin's lymphomaIndication
AdultIndication
Microsatellite Stable (MSS) Colon CancerIndication
Breast NeoplasmsIndication
Stomach AdenocarcinomaIndication
Esophageal AdenocarcinomaIndication
Esophageal CancerIndication
Inoperable DiseaseIndication
Glioblastoma MultiformeIndication
Grade IV AstrocytomaIndication
SarcomaIndication
Neuroendocrine Carcinoma, Grade IIIndication
Metastatic Neuroendocrine CarcinomaIndication
Lung Cancer Stage IVIndication
Large Cell Neuroendocrine CarcinomaIndication
Neuroendocrine TumorsIndication
Small Cell Lung Cancer MetastaticIndication
Metastatic Neuroendocrine NeoplasmIndication
Small Cell Neuroendocrine CarcinomaIndication
GliosarcomaIndication
MGMT promoter unmethylated glioblastomaIndication
AstrocytomaIndication
IDH-MutantIndication
Grade IVIndication
IDH WildtypeIndication
Indolent LymphomaIndication
autoimmune diseaseIndication
Crohn's DiseaseIndication
DermatomyositisIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Inflammatory Bowel DiseaseIndication
Multiple SclerosisIndication
PsoriasisIndication
Psoriatic ArthritisIndication
Rheumatoid ArthritisIndication
Systemic Lupus ErythematosusIndication
Systemic SclerosisIndication
ulcerative colitisIndication
Metastatic or Unresectable MelanomaIndication
ImmunotherapyIndication
Head and Neck NeoplasmsIndication
Pleural Biphasic MesotheliomaIndication
BCLC Stage B Hepatocellular CarcinomaIndication
BCLC Stage C Hepatocellular CarcinomaIndication
Malignant AscitesIndication
Endometrial CarcinosarcomaIndication
Down syndromeIndication
Sarcomatoid mesotheliomaIndication
malignantIndication
Cutaneous Melanoma AJCC v8Indication
Cutaneous Melanoma (Clinical Stage IB)Indication
Lung Cancer Stage IVA AJCC v8Indication
Stomach Cancer - Stage 0Indication
Gastroesophageal Junction AdenocarcinomaIndication
Stage I Gastric Cancer AJCC v8Indication
Gastric Cancer AJCC v8Indication
Stage 0 Gastric Cancer AJCC v8Indication
Stage I Gastric CancerIndication
Gastric Cancer, Stage IB, AJCC v8Indication
Stage IIIA Gastric Cancer AJCC v8Indication
Liver MetastasisIndication
Metastatic Carcinoma in the LungIndication
Castration-resistant Prostate CancerIndication
In-Transit MetastasisIndication
Gastric AdenocarcinomaIndication
Stage III Gastric CancerIndication
Stage IV Gastric CancerIndication
Chronic Lymphocytic LeukemiaIndication
Richter syndromeIndication
Small Lymphocytic LymphomaIndication
HepatocellularIndication
Resectable Hepatocellular CarcinomaIndication
Stage IV Colorectal CancerIndication
Colorectal Cancer MetastaticIndication
Nerve Sheath TumorsIndication
Bone MetastasisIndication
Sarcomatoid Renal Cell CarcinomaIndication
Bile Duct CancerIndication
Mycosis FungoidesIndication
Refractory Nodal Marginal Zone LymphomaIndication
Breast cancerIndication
Merkel Cell CarcinomaIndication
Pancreatic AdenocarcinomaIndication
Atypical Carcinoid TumorIndication
Lung Neuroendocrine NeoplasmIndication
Lung Non-Small Cell Squamous CarcinomaIndication
Lung AdenocarcinomaIndication
Recurrent Lung AdenocarcinomaIndication
Large Cell Carcinoma of the LungIndication
Lung Cancer stage IA3 AJCC v8Indication
Bladder Urothelial Carcinoma AJCC v7Indication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
Fallopian tube cancerIndication
Extrarenal originIndication
Clear Cell AdenocarcinomaIndication
fallopian tube carcinomaIndication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
NSCLCIndication
Pancoast TumorIndication
Gastrointestinal CancerIndication
Non-Small Cell Lung CarcinomaIndication
HER2/Neu NegativeIndication
Progesterone Receptor NegativeIndication
Stage 0 Breast CancerIndication
Breast Cancer AJCC Stage IAIndication
Stage IIA Breast CancerIndication
Stage IIIA Breast CancerIndication
Stage IIIB Breast CancerIndication
Adnexal CarcinomaIndication
Anaplastic Large Cell LymphomaIndication
ALK-NegativeIndication
ALK-positiveIndication
Apocrine CarcinomaIndication
Carcinoma Arising From CylindromaIndication
SpiradenomaIndication
Digital Papillary AdenocarcinomaIndication
Extramammary Paget DiseaseIndication
Sebaceous CarcinomaIndication
HidradenocarcinomaIndication
KeratoacanthomaIndication
Malignant Sweat Gland NeoplasmIndication
Microcystic Adnexal CarcinomaIndication
NK-Cell LymphomaIndication
UnclassifiableIndication
Breast Neoplasm FemaleIndication
Breast TumorIndication
Thyroid Gland Papillary CarcinomaIndication
Follicular Thyroid CarcinomaIndication
Oncocytic Thyroid CarcinomaIndication
pituitaryIndication
Pituitary TumorIndication
Pituitary CarcinomaIndication
Pituitary CancerIndication
Pediatric CancerIndication
Metastatic Lung CancerIndication
TumorIndication
NeoplasiaIndication
Non-Small Cell Lung Cancer MetastaticIndication
Follicular LymphomaIndication
Colorectal Cancer stage IV AJCC v8Indication
OcularIndication
CutaneousIndication
MucosalIndication
Metastatic renal cell carcinomaIndication
Renal Cell Cancer, Stage III (AJCC v7)Indication
Stage IV Cutaneous Merkel Cell CarcinomaIndication
Basal Cell CarcinomaIndication
Papillary AdenocarcinomaIndication
PorocarcinomaIndication
Primary Cutaneous Mucinous CarcinomaIndication
Recurrent T-Cell Non-Hodgkin LymphomaIndication
Refractory Skin Squamous Cell CarcinomaIndication
Refractory T-Cell Non-Hodgkin LymphomaIndication
Sezary SyndromeIndication
Adenoid Cystic CarcinomaIndication
Basosquamous Cell CarcinomaIndication
Squamoid Eccrine Ductal CarcinomaIndication
Eccrine Sweat Gland CarcinomaIndication
Trichilemmal CarcinomaIndication
Vulvar Squamous Cell CarcinomaIndication
LeiomyosarcomaIndication
Cutaneous Merkel Cell CarcinomaIndication
ST Elevation Myocardial InfarctionIndication
Non Small Cell Lung Cancer MetastaticIndication
Recurrent CancerIndication
Solid TumorIndication
Acral Lentiginous MelanomaIndication
Unresectable Mucosal MelanomaIndication
triple-negative breast cancerIndication
Ocular melanomaIndication
Castration-ResistantIndication
Small Intestinal AdenocarcinomaIndication
Small Intestinal Adenocarcinoma AJCC v8Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Indication
Melanoma of the Central Nervous SystemIndication
Leptomeningeal NeoplasmIndication
MelanocytomaIndication
Uveal MelanomaIndication
PainIndication
Diffuse Hemispheric GliomaIndication
H3 G34 mutationIndication
ChordomaIndication
Cervical AdenocarcinomaIndication
Cervical Adenosquamous CarcinomaIndication
Cervical Cancer Stage IVA AJCC v6 and v7Indication
Stage IVB Cervical CancerIndication
lung cancerIndication
Prostate AdenocarcinomaIndication
fallopian tubeIndication
Primary Peritoneal CancerIndication
Basaloid Squamous Cell CarcinomaIndication
Anal Canal Cloacogenic CarcinomaIndication
Anal Margin Squamous Cell CarcinomaIndication
Anal Cancer AJCC v8Indication
Esophageal NeoplasmsIndication
EsophagealIndication
Renal Cell Cancer MetastaticIndication
Non-small Cell Lung Cancer MetastaticIndication
pleural effusionIndication
Smoldering Plasma Cell MyelomaIndication
Solid TumorsIndication
Adrenal Gland NeoplasmsIndication
Neuroendocrine TumorIndication
GEP-NETIndication
Nasopharyngeal CancerIndication
Nasopharyngeal NeoplasmsIndication
Autoimmune DiseasesIndication
Arteritis, Giant CellIndication
Polymyalgia RheumaticaIndication
Squamous Cell Carcinoma of Head and NeckIndication
Rectal cancerIndication
Advanced or Metastatic Solid TumorsIndication
Liver metastatic carcinomaIndication
Liver CancerIndication
Liver cancerIndication
Stage IV Liver CancerIndication
Stage IVB Liver CancerIndication
Recurrent Follicular LymphomaIndication
Grade 2 Follicular LymphomaIndication
Grade 3 Follicular LymphomaIndication
Marginal Zone LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Mantle Cell LymphomaIndication
Recurrent Squamous Cell Lung CarcinomaIndication
Non-Small Cell LungIndication
Non-Small CellIndication
Lung Cancer Stage IIIIndication
Thymoma, Type B3Indication
Thymic CarcinomaIndication
Biliary Tract CancerIndication
Uterine Corpus Cancer (Stage III)Indication
Stage IV Uterine Corpus Cancer AJCC v8Indication
Recurrent Solid TumorsIndication
Hormone Receptor Positive TumorIndication
Relapsed Diffuse Large B-Cell LymphomaIndication
Drug EffectIndication
Head and NeckIndication
Squamous Cell Carcinoma of the MouthIndication
Oral Squamous Cell CarcinomaIndication
Hematopoietic/Lymphoid CancerIndication
Richter TransformationIndication
Esophageal Adenocarcinoma AJCC v8Indication
Gastric CancerIndication
Renal Pelvis CarcinomaIndication
Inoperable oesophageal CancerIndication
Urethral CarcinomaIndication
Bladder Cancer Stage III AJCC v8Indication
Stage III Renal Pelvis CancerIndication
Ureter Cancer AJCC v8Indication
Urethral Cancer AJCC v8Indication
Bladder Cancer AJCC v8Indication
Stage IV Renal Pelvis CancerIndication
Stage IV Ureter Cancer AJCC v8Indication
Urethral CancerIndication
Lung Cancer Stage IIIndication
TFE3-Rearranged Renal Cell CarcinomaIndication
ALK Gene RearrangementIndication
Complete Surgical ResectionIndication
Circulating Tumor DNAIndication
Anal MelanomaIndication
Bladder melanomaIndication
Esophageal MelanomaIndication
Melanoma of the GallbladderIndication
Mucosal Melanoma of the Head and NeckIndication
Melanoma of the Urinary SystemIndication
Nasopharyngeal MelanomaIndication
Oral Cavity Mucosal MelanomaIndication
Mucosal MelanomaIndication
Sinonasal Mucosal MelanomaIndication
Vulvar CancerIndication
Melanoma of the UrethraIndication
Clear Cell Renal Cell CarcinomaIndication
OncologyIndication
Infusion ReactionIndication
Metastatic Squamous Cell CarcinomaIndication
Acinar Cell CarcinomaIndication
Adrenal Cortical CarcinomaIndication
PheochromocytomaIndication
Anal Canal Undifferentiated CarcinomaIndication
AngiosarcomaIndication
Apocrine NeoplasmIndication
Appendiceal Mucinous AdenocarcinomaIndication
Bladder AdenocarcinomaIndication
Breast Metaplastic CarcinomaIndication
CholangiocarcinomaIndication
Colorectal Squamous Cell CarcinomaIndication
Desmoid FibromatosisIndication
Endometrial Transitional Cell CarcinomaIndication
Endometrioid AdenocarcinomaIndication
Esophageal Neuroendocrine CarcinomaIndication
Esophageal Undifferentiated CarcinomaIndication
Fallopian Tube AdenocarcinomaIndication
Fibromyxoid tumorIndication
Gallbladder CancerIndication
Gastric Neuroendocrine CarcinomaIndication
Stomach Squamous Cell CarcinomaIndication
Gastric Undifferentiated CarcinomaIndication
GISTIndication
Gestational Trophoblastic TumorIndication
Giant Cell CarcinomaIndication
Clear Cell-TypeIndication
Lung Neuroendocrine TumorIndication
Sarcomatoid Carcinoma of the LungIndication
Salivary Gland CarcinomaIndication
Odontogenic TumorsIndication
Malignant Peripheral Nerve Sheath TumorIndication
Testicular Sex Cord-Stromal TumorIndication
Pituitary Neuroendocrine TumorIndication
Mixed Mesodermal (Mullerian) TumorIndication
Mucinous CystadenocarcinomaIndication
Nasal Cavity AdenocarcinomaIndication
Nasal Cavity CarcinomaIndication
Oral Cavity CarcinomaIndication
Oropharyngeal Undifferentiated CarcinomaIndication
Ovarian AdenocarcinomaIndication
Ovarian Germ Cell TumorIndication
Ovarian Mucinous AdenocarcinomaIndication
Ovarian Squamous Cell CarcinomaIndication
Ovarian Transitional Cell CarcinomaIndication
Pancreatic Acinar Cell CarcinomaIndication
ParagangliomaIndication
Paranasal Sinus AdenocarcinomaIndication
Paranasal Sinus CarcinomaIndication
Parathyroid CarcinomaIndication
PEComaIndication
Penile Squamous Cell CarcinomaIndication
Peritoneal Mesothelial NeoplasmIndication
ChoriocarcinomaIndication
Pseudomyxoma peritoneiIndication
Rare DisorderIndication
Seminal Vesicle AdenocarcinomaIndication
Testicular seminomaIndication
Ovarian Serous CystadenocarcinomaIndication
Small Intestinal Squamous Cell CarcinomaIndication
Spindle Cell NeoplasmIndication
Teratoma With Malignant TransformationIndication
Testicular germ cell tumorIndication
Tracheal CancerIndication
Ureteral AdenocarcinomaIndication
Ureteral Squamous Cell CarcinomaIndication
Urethral AdenocarcinomaIndication
Urethral Squamous Cell CarcinomaIndication
Adenocarcinoma of the vaginaIndication
Vaginal Squamous Cell CarcinomaIndication
Vulvar CarcinomaIndication
Adenocarcinoma of the LungIndication
Lung Adenosquamous CarcinomaIndication
AIDS-Related Anal CarcinomaIndication
Anal Squamous Cell CarcinomaIndication
Rectal Squamous Cell CarcinomaIndication
Anal Cancer Stage I (AJCC v8)Indication
Oropharyngeal CarcinomaIndication
Basaloid Carcinoma of the OropharynxIndication
HPV-Mediated Oropharyngeal CarcinomaIndication
Posterior Tongue Squamous Cell CarcinomaIndication
Soft Palate Squamous Cell CarcinomaIndication
Tonsillar Squamous Cell CarcinomaIndication
Metastatic Solid TumorsIndication
Treatment-Refractory CancersIndication
Undifferentiated Pleomorphic SarcomaIndication
Oropharyngeal CancerIndication
Aggressive Non-Hodgkin LymphomaIndication
Solid NeoplasmIndication
T-Cell Non-Hodgkin LymphomaIndication
Central Nervous System MalignanciesIndication
Sjögren's syndromeIndication
HIV/AIDSIndication
Immune suppressionIndication
Colonic adenomaIndication
Lynch syndromeIndication
MLH1Indication
MSH2 Gene MutationIndication
Colon Cancer Stage IIIAbstract
Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).Org: Duke University Cancer Institute, Louisiana State University School of Medicine,
Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Phase 1 Trial: Porfimer Sodium Mediated Interstitial Photodynamic for the Treatment of Patients With Locally Advanced or Recurrent Head and Neck CancerStatus: Recruiting, Estimated PCD: 2024-12-10
Clinical trial
A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-22
Clinical trial
Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by OxaliplatinStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Repositioning Immunotherapy in Veterans With Lung CancerStatus: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-04-09
Clinical trial
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-08-13
Clinical trial
An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (> 65 Years) PatientsStatus: Completed, Estimated PCD: 2023-10-09
Clinical trial
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)Status: Active (not recruiting), Estimated PCD: 2025-01-30
Clinical trial
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-20
Clinical trial
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaStatus: Recruiting, Estimated PCD: 2027-07-16
Clinical trial
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-05
Clinical trial
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-05-26
Clinical trial
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab MonotherapyStatus: Terminated, Estimated PCD: 2020-07-28
Clinical trial
Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility StudyStatus: Recruiting, Estimated PCD: 2024-08-12
Clinical trial
A Phase II Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-07
Clinical trial
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS CancersStatus: Recruiting, Estimated PCD: 2026-04-21
Clinical trial
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerStatus: Terminated, Estimated PCD: 2022-04-18
Clinical trial
RadVax for Relapsed/Refractory Hodgkin's Lymphoma: A Phase II Trial of Nivolumab + Low Dose Radiotherapy for Incomplete RespondersStatus: Terminated, Estimated PCD: 2022-04-20
Clinical trial
Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (Anti-IL-8) for NSCLC or HCCStatus: Completed, Estimated PCD: 2023-11-16
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)Status: Terminated, Estimated PCD: 2023-03-24
Clinical trial
H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC With and Without PD-1 Inhibition Using Nivolumab for the Treatment of Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive GliomasStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2022-07-01
Clinical trial
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)Status: Active (not recruiting), Estimated PCD: 2021-10-28
Clinical trial
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 TherapyStatus: Active (not recruiting), Estimated PCD: 2022-01-05
Clinical trial
ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaStatus: Terminated, Estimated PCD: 2022-10-18
Clinical trial
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Phase I/II Open-Label Study of Nimotuzumab in Combination With Nivolumab in Patients With Advanced Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2021-04-15
Clinical trial
A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line TreatmentStatus: Completed, Estimated PCD: 2023-12-20
Clinical trial
Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseStatus: Completed, Estimated PCD: 2020-08-20
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of VB-111 in Combination With Nivolumab in Patients With Metastatic Colorectal Cancer (mCRC).Status: Completed, Estimated PCD: 2022-04-12
Clinical trial
A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer PatientsStatus: , Estimated PCD: 2025-11-01
Clinical trial
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Evaluation of Costs and Outcomes of the Implementation of Treatment Protocol Based on Rational Utilization of Anti-PD1 Agents in Patients With Non-small-cell Lung Cancer in the Brazilian Public Health SystemStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsStatus: Recruiting, Estimated PCD: 2027-01-23
Clinical trial
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-09
Clinical trial
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination With Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation.Status: Active (not recruiting), Estimated PCD: 2024-05-24
Clinical trial
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial CancerStatus: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayStatus: Terminated, Estimated PCD: 2021-06-01
Clinical trial
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-11
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkinStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal CancerStatus: Completed, Estimated PCD: 2021-10-28
Clinical trial
A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Study Evaluating the Efficacy of Anti-CD38 Antibody in Combination With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced MelanomaStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and IpilimumabStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With IpilimumabStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or ProgressionStatus: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.Status: Active (not recruiting), Estimated PCD: 2027-11-30
Clinical trial
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS LymphomaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma With Innate Anti-PD-1 ResistanceStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast CancerStatus: Completed, Estimated PCD: 2024-06-07
Clinical trial
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive TherapyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Irreversible Electroporation in Combination With Immune Checkpoint Inhibition, in Patients With Metastatic Pancreatic Cancer - A Prospective, Phase 2 StudyStatus: Terminated, Estimated PCD: 2023-08-30
Clinical trial
An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Nivolumab (Anti-PD1 Antibody) and Ipilimumab (Anti-CTLA4 Antibody) in Combination With Immunogenic Chemotherapy for Patients With Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)Status: Not yet recruiting, Estimated PCD: 2028-05-15
Clinical trial
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable SarcomaStatus: Completed, Estimated PCD: 2019-04-01
Clinical trial
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLCStatus: Completed, Estimated PCD: 2022-05-09
Clinical trial
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 StudyStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory NeuroblastomaStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal JunctionStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)Status: Completed, Estimated PCD: 2021-07-19
Clinical trial
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed MeningiomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-03-06
Clinical trial
Graft-Versus-Tumor Augmentation With Nivolumab for High-Risk Patients With MDS and AML After Allogeneic Stem Cell Transplantation Using Post-Transplantation CyclophosphamideStatus: Withdrawn, Estimated PCD: 2021-04-20
Clinical trial
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)Status: Not yet recruiting, Estimated PCD: 2027-01-30
Clinical trial
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular CarcinomaStatus: , Estimated PCD: 2025-07-31
Clinical trial
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II TrialStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-14
Clinical trial
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet ChemotherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)Status: Terminated, Estimated PCD: 2023-10-19
Clinical trial
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2022-11-04
Clinical trial
A Phase II Study of Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) Administered in Combination With Anti-LAG3 Monoclonal Antibody (Relatlimab, BMS-986016) in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingStatus: Active (not recruiting), Estimated PCD: 2027-07-31
Clinical trial
Phase 2 Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable OsteosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentStatus: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine CarcinomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2023-04-13
Clinical trial
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 GliomaStatus: , Estimated PCD: 2025-05-31
Clinical trial
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Phase 2, Open-label, Two Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib or Cabozantinib Plus Nivolumab on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase II Trial of Nivolumab in Combination With Talazoparib in Patients With Unresectable or Metastatic Melanoma and Mutations in BRCA or BRCA-ness GenesStatus: Completed, Estimated PCD: 2023-10-13
Clinical trial
A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced Or Recurrent Head and Neck Carcinoma. Subtitle: Hypoxia as a Determinant for the Effect of Nivolumab With or Without Ipilimumab on Intra-tumoral T Cell CapacityStatus: Completed, Estimated PCD: 2019-10-12
Clinical trial
Official Title Neoadjuvant Immunotherapy in Sarcomatoid MesotheliomaStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative BiomarkersStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
The Effect of Intraperitoneal Immune Checkpoint Inhibitor on Malignant Ascites of Patients With Gastric, Pancreatic or Biliary Tract CancerStatus: , Estimated PCD: 2026-12-01
Clinical trial
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-04-11
Clinical trial
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First RelapseStatus: , Estimated PCD: 2028-06-30
Clinical trial
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)Status: Recruiting, Estimated PCD: 2028-06-15
Clinical trial
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade GliomasStatus: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
Intralesional Influenza Vaccine for Patients With MelanomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2023-12-07
Clinical trial
Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLCStatus: Terminated, Estimated PCD: 2020-10-07
Clinical trial
A Single Arm Study of Vidutolimod (CMP-001) With Nivolumab in Patients With Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2027-06-23
Clinical trial
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)Status: Active (not recruiting), Estimated PCD: 2026-12-30
Clinical trial
Biomarker Driven Patient Selection for Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma: A Pilot StudyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-29
Clinical trial
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial CarcinomaStatus: Completed, Estimated PCD: 2022-08-08
Clinical trial
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase I/II Intratumoral Administration of Hu14.18-IL2, With Local Radiation, Nivolumab and Ipilimumab in Subjects With Advanced MelanomaStatus: , Estimated PCD: 2024-08-15
Clinical trial
A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 TherapyStatus: Terminated, Estimated PCD: 2023-05-29
Clinical trial
A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 TherapyStatus: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular CarcinomaStatus: Terminated, Estimated PCD: 2020-11-24
Clinical trial
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate CancerStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP TrialStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-11-08
Clinical trial
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and ImmunotherapyStatus: Recruiting, Estimated PCD: 2028-06-16
Clinical trial
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular LymphomaStatus: Completed, Estimated PCD: 2024-02-14
Clinical trial
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingStatus: Completed, Estimated PCD: 2024-02-16
Clinical trial
A Phase II Single-arm, Open-label Study of Transarterial Chemoembolization (TACE) in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (HCC)Status: Completed, Estimated PCD: 2021-10-12
Clinical trial
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-11
Clinical trial
A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Phase II Study of Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaStatus: , Estimated PCD: 2023-03-03
Clinical trial
Phase II Trial of Nivolumab and Metformin in Patients With Treatment Refractory MSS Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]Status: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint InhibitorsStatus: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PETStatus: , Estimated PCD: 2025-04-01
Clinical trial
A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-04-15
Clinical trial
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-04-06
Clinical trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational TrialStatus: Active (not recruiting), Estimated PCD: 2024-02-22
Clinical trial
Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeStatus: Completed, Estimated PCD: 2023-04-21
Clinical trial
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in FinlandStatus: Completed, Estimated PCD: 2024-04-10
Clinical trial
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaStatus: Terminated, Estimated PCD: 2021-01-31
Clinical trial
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deletedStatus: Terminated, Estimated PCD: 2023-05-17
Clinical trial
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase 1 Trial of PANtoTHEnic Acid in Patient With Metastatic or Unresectable Melanoma ON ImmunOtherapy (PANTHEON-IO)Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer: a Multicenter Single-arm Phase II TrialStatus: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyStatus: Active (not recruiting), Estimated PCD: 2023-02-07
Clinical trial
Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory StudyStatus: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological CancersStatus: Active (not recruiting), Estimated PCD: 2020-04-27
Clinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesStatus: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage HepatocellularStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]Status: Completed, Estimated PCD: 2023-03-12
Clinical trial
A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination With Nivolumab, in Patients With Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer Who Have Progressed Following Therapy With Current Standard of Care (PORCUPINE)Status: Completed, Estimated PCD: 2024-04-02
Clinical trial
ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric CancerStatus: Completed, Estimated PCD: 2020-01-01
Clinical trial
Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
A Randomized Pilot Study to Investigate the Safety and Immunologic Impact of Evolocumab When Given in Combination With Ipilimumab and Nivolumab in Treatment-Naïve Patients With Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-11-08
Clinical trial
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaStatus: Terminated, Estimated PCD: 2020-09-24
Clinical trial
A Phase Ib Trial of PBF-1129 and Nivolumab in Patients With Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)Status: Active (not recruiting), Estimated PCD: 2023-06-13
Clinical trial
A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-01-11
Clinical trial
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted TherapyStatus: Completed, Estimated PCD: 2022-09-06
Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2022-10-11
Clinical trial
Phase II Study of Rucaparib and Nivolumab in Patients With LeiomyosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-11-05
Clinical trial
A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)Status: Recruiting, Estimated PCD: 2026-08-29
Clinical trial
Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)Status: Terminated, Estimated PCD: 2022-03-11
Clinical trial
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical ActivityStatus: Completed, Estimated PCD: 2021-02-21
Clinical trial
A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288Status: Active (not recruiting), Estimated PCD: 2024-03-13
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-RespondersStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease (LMD)Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate CancerStatus: Completed, Estimated PCD: 2022-02-02
Clinical trial
A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-MutantStatus: Not yet recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Signal Finding Phase 2 Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) and Relatlimab (Anti-LAG-3 Monoclonal Antibody; BMS-986016) in Patients With Advanced ChordomaStatus: Completed, Estimated PCD: 2023-09-28
Clinical trial
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical CancerStatus: Active (not recruiting), Estimated PCD: 2019-03-05
Clinical trial
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain MetastasesStatus: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater RemissionStatus: Completed, Estimated PCD: 2023-04-06
Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)Status: Recruiting, Estimated PCD: 2025-04-09
Clinical trial
Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLCStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2018-09-05
Clinical trial
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)Status: Completed, Estimated PCD: 2019-12-09
Clinical trial
GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced SarcomaStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Efficacy and Safety of the Combination of Cisplatin Plus Nab-paclitaxel and Nivolumab With Radiotherapy After Maximal Tumor Resection in Non-metastatic Muscle Invasive Bladder Cancer.Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerStatus: Recruiting, Estimated PCD: 2034-12-30
Clinical trial
A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Phase 1 Study of Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Stereotactic Body Radiotherapy for Refractory Pancreatic Cancer (CheckVAC)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2023-02-24
Clinical trial
Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy: An Open-label Phase II GERCOR TrialStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase II Trial of Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.Status: Completed, Estimated PCD: 2023-03-01
Clinical trial
Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple MyelomaStatus: Completed, Estimated PCD: 2018-06-28
Clinical trial
Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid TumorsStatus: Completed, Estimated PCD: 2021-11-30
Clinical trial
An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2024-07-08
Clinical trial
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-05-27
Clinical trial
The Effect of Prebiotic Inulin on Patients Affected by Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Treated With Immune Checkpoint Inhibitors (ICIs): Princess StudyStatus: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
A Phase II Study of Platinum-doublet Chemotherapy in Combination With Nivolumab as First-line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic G3 Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.Status: Active (not recruiting), Estimated PCD: 2023-02-13
Clinical trial
A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-31
Clinical trial
Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-09
Clinical trial
Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group TrialStatus: Active (not recruiting), Estimated PCD: 2019-03-01
Clinical trial
A Pre-Operative Study Evaluating Nivolumab Plus ADI-PEG 20 in Patients With Resectable Hepatocellular CarcinomaStatus: Withdrawn, Estimated PCD: 2023-02-10
Clinical trial
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint InhibitionStatus: Completed, Estimated PCD: 2021-02-28
Clinical trial
Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseStatus: Terminated, Estimated PCD: 2021-03-18
Clinical trial
T-cell Therapy in Combination With Checkpoint Inhibitors for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and NeckStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase I Trial Assessing the Safety and Efficacy of an Anti-tumor Immunity Priming Strategy Combining Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 StudyStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal AdenocarcinomaStatus: , Estimated PCD: 2026-12-31
Clinical trial
A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab VedotinStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityStatus: Active (not recruiting), Estimated PCD: 2019-07-01
Clinical trial
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)Status: Active (not recruiting), Estimated PCD: 2019-12-19
Clinical trial
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk StratificationStatus: Active (not recruiting), Estimated PCD: 2027-09-01
Clinical trial
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLCStatus: Terminated, Estimated PCD: 2021-10-22
Clinical trial
Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid TumorStatus: Completed, Estimated PCD: 2014-12-01
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-04-10
Clinical trial
A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Patients With Metastatic Hormone Reseptor Positive Breast CancerStatus: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients.Status: Completed, Estimated PCD: 2021-04-01
Clinical trial
A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant ChemotherapyStatus: Completed, Estimated PCD: 2022-08-17
Clinical trial
ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid TumorStatus: Completed, Estimated PCD: 2015-06-01
Clinical trial
Treatment With Nivolumab and All-trans Retinoic Acid for Patients With Refractory Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Recruiting, Estimated PCD: 2033-06-30
Clinical trial
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)Status: Completed, Estimated PCD: 2020-02-18
Clinical trial
A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationStatus: Terminated, Estimated PCD: 2022-02-11
Clinical trial
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin LymphomaStatus: , Estimated PCD: 2025-03-20
Clinical trial
A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)Status: Completed, Estimated PCD: 2020-02-10
Clinical trial
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- IpilimumabStatus: Terminated, Estimated PCD: 2022-10-07
Clinical trial
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)Status: Completed, Estimated PCD: 2024-04-29
Clinical trial
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialStatus: Recruiting, Estimated PCD: 2025-10-10
Clinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-06
Clinical trial
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With MelanomaStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as "Chemotherapy") Versus Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Status: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular CarcinomaStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2024-05-12
Clinical trial
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyStatus: Withdrawn, Estimated PCD: 2023-05-03
Clinical trial
Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Real-World Evaluation of Patient Characteristics, Treatment Patterns, Safety, and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab for Pediatric MelanomaStatus: Completed, Estimated PCD: 2023-09-25
Clinical trial
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)Status: Active (not recruiting), Estimated PCD: 2024-12-08
Clinical trial
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age GroupsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2020-02-29
Clinical trial
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)Status: Active (not recruiting), Estimated PCD: 2023-05-24
Clinical trial
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)Status: Active (not recruiting), Estimated PCD: 2022-10-19
Clinical trial
A Pilot Study of Intratumoral SD-101 (Toll-Like Receptor 9 Agonist), Nivolumab, and Radiotherapy for Treatment of Chemotherapy-Refractory Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2021-12-03
Clinical trial
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
A Pilot Trial of Ipilimumab-Nivolumab in Local-Regionally Advanced Non Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer ResectionStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment BiopsyStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)Status: Terminated, Estimated PCD: 2022-09-25
Clinical trial
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal MelanomaStatus: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
Pilot, Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant LesionsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-10-19
Clinical trial
A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Perioperative Immunotherapy vs. Chemo-immunotherapy Stratified by Early Response Evaluation in Patients With Advanced Gastric Cancer (GC) and Adenocarcinoma of the Esophago-gastric Junction (AEG)Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse EventsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF MutationStatus: Completed, Estimated PCD: 2024-05-31
Clinical trial
Phase IIA Basket Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)Status: Completed, Estimated PCD: 2024-02-05
Clinical trial
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-04-04
Clinical trial
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II TrialStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective StudyStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage TherapyStatus: Active (not recruiting), Estimated PCD: 2023-03-01
Clinical trial
A Pilot, Rapid Sequencing of First Line Cabozantinib, Ipilimumab and Nivolumab, and Lenvatinib and Everolimus in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Biomarker Driven Phase 1/1b Trial of ASTX727 and Nivolumab in Patients With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Not yet recruiting, Estimated PCD: 2025-02-28
Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Risk-Adapted Therapy for HIV-Associated Anal CancerStatus: Recruiting, Estimated PCD: 2029-09-15
Clinical trial
A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-08-03
Clinical trial
Combination of Nivolumab and Ipilimumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects With Refractory CancersStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial)Status: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue SarcomaStatus: , Estimated PCD: 2026-05-15
Clinical trial
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2020-09-08
Clinical trial
A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerStatus: Active (not recruiting), Estimated PCD: 2022-04-01
Abstract
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,
Abstract
A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.Org: Memorial Sloan Kettering Cancer Center, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sarcoma Medical Oncology Service,
Abstract
Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers.Org: Department of Dermatology, University Hospital of Zurich, University Hospital Zurich, University Hospital Zurich - USZ, Dept. of Dermatology, University Hospital Zürich, University of Zurich and University Hospital Zurich,
Clinical trial
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair GenesStatus: Completed, Estimated PCD: 2018-03-11
Clinical trial
Immunotherapy Sequencing in COlon and REctal CancerStatus: Active (not recruiting), Estimated PCD: 2022-10-21
Clinical trial
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Phase 1 Study to Evaluate the Safety, Feasibility and Immunologic Correlatives of Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic DriversStatus: Terminated, Estimated PCD: 2018-01-08
Clinical trial
A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial ColectomyStatus: Terminated, Estimated PCD: 2021-01-25
Clinical trial
A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-03-01